Reneuro (choline alfoscerate) solution for injections 250 mg/ml. 4 ml. ampoules №5

Description

Reneuro (choline alfoscerate) solution for injections 250 mg/ml. 4 ml. ampoules №5

Composition

active ingredient: choline alfoscerate;

1 ml of solution contains choline alfoscerate 250 mg;

excipients: water for injection.

Dosage form

Injection.

Basic physical and chemical properties: transparent, colorless or yellowish liquid.

Pharmacological group

Drugs affecting the nervous system. Parasympathomimetics. Other parasympathomimetics. Choline alfoscerate.
Code ATX N07A X02.

Pharmacological properties

Reneuro is a drug that belongs to the group of central cholinomimetics with a predominant effect on the CNS. Choline alfoscerate as a carrier of choline and a precursor of phosphatidylcholine has the potential to prevent and correct biochemical damage, which is of particular importance among the pathogenic factors of psychoorganic involution syndrome, ie it can affect reduced cholinergic tone and altered phospholipid cell phospholipids. 40.5% of the drug consists of metabolically protected choline. Metabolic protection provides the release of choline in the brain. Reneuro has a positive effect on memory and cognitive functions, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.

The mechanism of action is based on the fact that when choline enters the body, alfoscerate is broken down by enzymes into choline and glycerophosphate: choline is taught in the biosynthesis of acetylcholine – one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. Thus, the drug Reneuro improves the transmission of nerve impulses in cholinergic neurons, has a positive effect on the plasticity of neuronal membranes and receptor function. The drug Reneuro improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.

Indication

Acute period of severe traumatic brain injury with predominantly stem level of damage (disturbance of consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage).

Degenerative-involutional cerebral psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, ie primary and secondary mental disorders in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional sphere and the sphere of behavior: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.

Contraindication:

• known hypersensitivity to the drug or its components;
• psychotic syndrome with severe psychomotor arousal;
• pregnancy and breastfeeding.

Method of application and dosage

In acute conditions, Reneuro solution is administered intramuscularly or intravenously (slowly) in 1 g (1 ampoule) per day for 15-20 days. Then, after stabilization of the patient’s condition, switch to oral dosage form of choline alfoscerate.

Children

There is no experience with the use of the drug Reneuro solution in children.

Overdose

In case of overdose of Reneuro , which may be manifested by nausea, the dose should be reduced. Therapy is symptomatic.

Side effects

The drug is usually well tolerated even with prolonged use. Possible reactions at the injection site. During the first days or weeks of treatment, the following side effects may occur: anxiety, agitation, insomnia. These symptoms are temporary and do not require discontinuation of treatment, but a temporary dose reduction is possible.
Nausea (mainly due to secondary dopaminergic activation), low blood pressure, headache, very rarely abdominal pain and short-term confusion are possible. In this case, it is necessary to reduce the dose of the drug.
Possible hypersensitivity reactions, including rash, pruritus, urticaria, angioneurotic edema, reddening of the skin.